no BE between early phase and Phase 3 formulations [Regulatives / Guidelines]

posted by Helmut Homepage – Vienna, Austria, 2020-01-22 17:15 (1110 d 11:21 ago) – Posting: # 21079
Views: 2,234

Hi Fabrice,

❝ Is FDA requiring a formal BE demonstration for bridging the early phase with the Phase 3 formulations?

❝ If so, what would be the required actions in case the Phase 3 formulation is not perfectly bioequivalent to the previously used formulation?


Without digging into guidelines: No. What we have in Phase I/II is sometimes not what I would call a ‘formulation’ in the biopharmaceutical sense at all. Anything goes: Manually filled capsules, lab-scale tablet-presses, etc. Doesn’t matter because we are interested in PK (I) and safety (II). Once you move to phase III you are bound to cGMP (though still in pilot-scale). Only when you move from III to the to be marketed formulation, the applicable SUPAC guidance (IR, MR, SS) cut in and very likely you need a BE study.

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
22,479 posts in 4,709 threads, 1,603 registered users;
24 visitors (0 registered, 24 guests [including 11 identified bots]).
Forum time: 04:37 CET (Europe/Vienna)

The rise of biometry in this 20th century,
like that of geometry in the 3rd century before Christ,
seems to mark out one of the great ages or critical periods
in the advance of the human understanding.    R.A. Fisher

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5